EUVIMEDEUVIMED entdecken
Crossref

Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma

Yu-Lu Mao iD, Ben-Yuan Mao, Yu-Long Ouyang iD, Yi Zhang, Ping Cheng, Hong-Chao Feng

Oral Diseases · 15.07.2026

DOI: 10.1111/odi.70401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 15.07.2026. Verfasst von Yu-Lu Mao und 5 weiteren Autor:innen. Beteiligte Einrichtung: GuiZhou University Medical College, Guiyang, Guizhou Province, China. Hauptthemen laut MEDLINE: Cisplatin, Tongue Neoplasms, Drug Resistance, Neoplasm, Mercaptopurine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the Guiyang Stomatological Hospital High-level Talents Program, Health Commission of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cisplatin resistance remains a major clinical obstacle in the treatment of tongue squamous cell carcinoma (TSCC). Solute carrier family 7 member 2 (SLC7A2) is a key cationic amino acid transporter, yet its functional significance in TSCC drug resistance has not been explored.

Methods

We established cisplatin‐resistant TSCC cell lines and performed integrated proteomics and metabolomics. SLC7A2 function was assessed via gain‐of‐function and loss‐of‐function assays combined with CCK‐8, Transwell, wound healing, flow cytometry, Western blot, and RT‐qPCR.

Results

SLC7A2 was markedly downregulated in both TSCC tissues and cisplatin‐resistant cells. Multi‐omics analysis revealed significant perturbations in purine metabolism, identifying 6‐mercaptopurine (6‐MP) as a critical metabolite. SLC7A2 overexpression or combined Cis+6‐MP treatment synergistically suppressed proliferation, migration, and invasion while promoting apoptosis. Mechanistically, SLC7A2 expression correlated with p53 signaling activity: SLC7A2 knockdown increased MDM2 expression and induced cisplatin resistance, while SLC7A2 overexpression or Cis+6‐MP treatment reversed these effects. Pharmacological inhibition of p53 with PFT‐α sensitized cells to cisplatin, whereas p53 activation with Nutlin‐3a partially reversed resistance in a p53‐dependent manner.

Conclusion

This study identifies SLC7A2 as a regulator of cisplatin response in TSCC, acting through the p53 signaling network. It also highlights 6‐MP as a sensitizer, offering a combination strategy to overcome chemoresistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinTongue NeoplasmsDrug Resistance, NeoplasmMercaptopurineCarcinoma, Squamous CellPurinesAntineoplastic AgentsHumansCell Line, TumorCell ProliferationApoptosisCell MovementTumor Suppressor Protein p53Proto-Oncogene Proteins c-mdm2Down-Regulation

Stichwörter der Autor:innen

6‐mercaptopurineSLC7A2amino acid metabolismcisplatin resistancetongue squamous cell carcinoma

Substanzen

CisplatinMercaptopurinePurinesAntineoplastic AgentsTumor Suppressor Protein p53purineProto-Oncogene Proteins c-mdm2

Autor:innen und Institutionen

  • GuiZhou University Medical College, Guiyang, Guizhou Province, China.
  • Department of Oral and Maxillofacial Surgery, Guiyang Stomatological Hospital, Guiyang, China.
  • College of Stomatology, Guizhou Medical University, Guiyang, China.
  • Department of Clinical Laboratory, Guiyang Stomatological Hospital, Guiyang, China.

ORCID-Profile: Yu-Lu Mao, Yu-Long Ouyang

Förderung

  • the Guiyang Stomatological Hospital High-level Talents Program
  • Health Commission of Guizhou Province

Zitieren

APA

Mao, Y. L., Mao, B. Y., Ouyang, Y. L., Zhang, Y., Cheng, P., & Feng, H. C. (2026). Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma. Oral Diseases. https://doi.org/10.1111/odi.70401

Vancouver

Mao YL, Mao BY, Ouyang YL, Zhang Y, Cheng P, Feng HC. Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma. Oral Diseases. 2026. doi:10.1111/odi.70401

BibTeX
@article{Mao2026,
  author = {Mao, Yu-Lu and Mao, Ben-Yuan and Ouyang, Yu-Long and Zhang, Yi and Cheng, Ping and Feng, Hong-Chao},
  title = {Targeting Purine Metabolism With 6‐Mercaptopurine Overcomes Solute Carrier Family 7 Member 2 Deficiency‐Induced Cisplatin Resistance in Tongue Squamous Cell Carcinoma},
  journal = {Oral Diseases},
  year = {2026},
  doi = {10.1111/odi.70401}
}
Kostenlos starten →